

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHENZHEN DOBOT CORP LTD
深圳市越疆科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2432)

**ENTERING INTO STRATEGIC COOPERATION AND BUSINESS
DEPLOYMENT AGREEMENT**

The board of directors (the “**Board**”) of SHENZHEN DOBOT CORP LTD (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that on 3 June 2025, the Group entered into a strategic cooperation and business deployment agreement (the “**Strategic Agreement**”) with the group of YSB Inc. (the shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited, stock code: 09885.HK) (“**YSB**”), pursuant to which a close strategic cooperation was initiated, together with the commencement of concrete project deployments. To the best knowledge and information of the directors of the Company, having made all reasonable enquiries, YSB and its ultimate beneficial owners are third parties independent of the Company and its connected person (as defined under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited).

BACKGROUND OF THE COOPERATION

Founded in 2015, the Group is one of leading companies that specialises in the development, manufacturing and commercialisation of collaborative robots, or commonly known as “**cobots**”. Leveraging its proprietary full-stack cobot development technologies, the Group has launched over 20 cobots to cater to the needs in various scenarios such as medical and healthcare, automotive, semiconductor, chemical and new retail, solidifying its position as an industry benchmark. Founded in 2015, YSB has been dedicated to the outside-of-hospital pharmaceutical market and primary healthcare sector since its establishment. It strives to empower a wide range of enterprises in the upstream and downstream of the pharmaceutical industry, and deliver digital and intelligent solutions to monomer pharmacies and chain pharmacies as well as primary healthcare institutions.

According to an industry report issued by China Insights Industry Consultancy Limited, the global cobot market for the medical and healthcare sector is expected to reach US\$373.2 million in 2028. The Group also expects the robot market to continue to grow significantly, with the medical and healthcare sector becoming an important scenario for the application and promotion of cobots.

SUMMARY OF THE STRATEGIC AGREEMENT

Based on the long-standing industry leadership of both parties and highly synergistic business ecosystems, the Group and YSB have decided to establish a comprehensive strategic cooperation partnership to jointly explore the whole-chain scenario application of cobots and related artificial intelligence (“AI”) products in the fields of pharmaceutical research and development (“R&D”), warehousing, delivery, retailing and medication services by focusing on the core technologies of pharmaceutical cobots, pharmaceutical AI large models and the IoT of pharmaceuticals, with a view to promoting the integration and upgrading of robotics and pharmaceutical industry and achieving the Group’s vision of “Realise optimal human-machine collaboration (實現人機協作的最優配置)” and YSB’s mission of “To make quality medical care and good medicine accessible to all (讓好醫好藥普惠可及)”. Both parties will focus on cooperation in the area of pharmaceutical cobots. YSB is mainly responsible for researching and justifying the application scenarios and demand matching degree, providing robotic working environment interface, and is fully responsible for the subsequent promotion and sales of cobot products. The Group is responsible for matters including the technical R&D, the hardware and software implementation for cobots, product manufacturing, technical training and after-sales maintenance.

UPDATE ON BUSINESS DEPLOYMENT PROGRESS

At the initial stage of the strategic cooperation, both parties will commence cooperation in the field of pharmacies and pharmaceutical warehousing cobots. Currently, both parties have finalised the plan for the first landing project, and have completed the feasibility study, technical route research and judgement, exchange of technical solutions, and selection of suitable deployment environment, and have begun to build a test platform.

Both parties will follow the principles of collaborative innovation and win-win development in the cooperation, and share technical materials as well as newly generated intellectual property rights and business secrets during the cooperation. Under the terms of the agreement, the Group shall have the exclusive right to produce the robots of this project whilst YSB shall have the exclusive right to sell the same in the pharmaceutical industry. Based on this project and leveraging the respective strength, both parties will continue to embark on more new projects under the framework of the Strategic Agreement.

The Board of the Group believes that the establishment of the strategic cooperation relationship with YSB is conducive to the integration of resources and collaborative innovation, so as to make full use of the industry-leading advantages of both parties to promote industrial technology development and enhance the health and well-being of the society.

Shareholders of the Company and potential investors should note that this announcement is for the purpose of keeping the public informed of the latest business development of the Company. The Company will make further announcement in compliance with the Listing Rules (where applicable). Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Company's shares.

By order of the Board
SHENZHEN DOBOT CORP LTD
Mr. Liu Peichao

*Chairman of the Board, Executive Director
and General Manager*

Shenzhen, 3 June 2025

As at the date of this announcement, the Board comprises (i) Mr. Liu Peichao, Mr. Wang Yong and Mr. Lang Xulin as executive directors; (ii) Mr. Jing Liang as non-executive director; and (iii) Mr. Li Yibin, Mr. Ng Jack Ho Wan and Dr. Hou Lingling as independent non-executive directors.